Cargando…
An oncogenic role for sphingosine kinase 2
While both human sphingosine kinases (SK1 and SK2) catalyze the generation of the pleiotropic signaling lipid sphingosine 1-phosphate, these enzymes appear to be functionally distinct. SK1 has well described roles in promoting cell survival, proliferation and neoplastic transformation. The roles of...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323123/ https://www.ncbi.nlm.nih.gov/pubmed/27588496 http://dx.doi.org/10.18632/oncotarget.11714 |
_version_ | 1782509970992922624 |
---|---|
author | Neubauer, Heidi A. Pham, Duyen H. Zebol, Julia R. Moretti, Paul A.B. Peterson, Amanda L. Leclercq, Tamara M. Chan, Huasheng Powell, Jason A. Pitman, Melissa R. Samuel, Michael S. Bonder, Claudine S. Creek, Darren J. Gliddon, Briony L. Pitson, Stuart M. |
author_facet | Neubauer, Heidi A. Pham, Duyen H. Zebol, Julia R. Moretti, Paul A.B. Peterson, Amanda L. Leclercq, Tamara M. Chan, Huasheng Powell, Jason A. Pitman, Melissa R. Samuel, Michael S. Bonder, Claudine S. Creek, Darren J. Gliddon, Briony L. Pitson, Stuart M. |
author_sort | Neubauer, Heidi A. |
collection | PubMed |
description | While both human sphingosine kinases (SK1 and SK2) catalyze the generation of the pleiotropic signaling lipid sphingosine 1-phosphate, these enzymes appear to be functionally distinct. SK1 has well described roles in promoting cell survival, proliferation and neoplastic transformation. The roles of SK2, and its contribution to cancer, however, are much less clear. Some studies have suggested an anti-proliferative/pro-apoptotic function for SK2, while others indicate it has a pro-survival role and its inhibition can have anti-cancer effects. Our analysis of gene expression data revealed that SK2 is upregulated in many human cancers, but only to a small extent (up to 2.5-fold over normal tissue). Based on these findings, we examined the effect of different levels of cellular SK2 and showed that high-level overexpression reduced cell proliferation and survival, and increased cellular ceramide levels. In contrast, however, low-level SK2 overexpression promoted cell survival and proliferation, and induced neoplastic transformation in vivo. These findings coincided with decreased nuclear localization and increased plasma membrane localization of SK2, as well as increases in extracellular S1P formation. Hence, we have shown for the first time that SK2 can have a direct role in promoting oncogenesis, supporting the use of SK2-specific inhibitors as anti-cancer agents. |
format | Online Article Text |
id | pubmed-5323123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53231232017-03-23 An oncogenic role for sphingosine kinase 2 Neubauer, Heidi A. Pham, Duyen H. Zebol, Julia R. Moretti, Paul A.B. Peterson, Amanda L. Leclercq, Tamara M. Chan, Huasheng Powell, Jason A. Pitman, Melissa R. Samuel, Michael S. Bonder, Claudine S. Creek, Darren J. Gliddon, Briony L. Pitson, Stuart M. Oncotarget Research Paper While both human sphingosine kinases (SK1 and SK2) catalyze the generation of the pleiotropic signaling lipid sphingosine 1-phosphate, these enzymes appear to be functionally distinct. SK1 has well described roles in promoting cell survival, proliferation and neoplastic transformation. The roles of SK2, and its contribution to cancer, however, are much less clear. Some studies have suggested an anti-proliferative/pro-apoptotic function for SK2, while others indicate it has a pro-survival role and its inhibition can have anti-cancer effects. Our analysis of gene expression data revealed that SK2 is upregulated in many human cancers, but only to a small extent (up to 2.5-fold over normal tissue). Based on these findings, we examined the effect of different levels of cellular SK2 and showed that high-level overexpression reduced cell proliferation and survival, and increased cellular ceramide levels. In contrast, however, low-level SK2 overexpression promoted cell survival and proliferation, and induced neoplastic transformation in vivo. These findings coincided with decreased nuclear localization and increased plasma membrane localization of SK2, as well as increases in extracellular S1P formation. Hence, we have shown for the first time that SK2 can have a direct role in promoting oncogenesis, supporting the use of SK2-specific inhibitors as anti-cancer agents. Impact Journals LLC 2016-08-30 /pmc/articles/PMC5323123/ /pubmed/27588496 http://dx.doi.org/10.18632/oncotarget.11714 Text en Copyright: © 2016 Neubauer et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Neubauer, Heidi A. Pham, Duyen H. Zebol, Julia R. Moretti, Paul A.B. Peterson, Amanda L. Leclercq, Tamara M. Chan, Huasheng Powell, Jason A. Pitman, Melissa R. Samuel, Michael S. Bonder, Claudine S. Creek, Darren J. Gliddon, Briony L. Pitson, Stuart M. An oncogenic role for sphingosine kinase 2 |
title | An oncogenic role for sphingosine kinase 2 |
title_full | An oncogenic role for sphingosine kinase 2 |
title_fullStr | An oncogenic role for sphingosine kinase 2 |
title_full_unstemmed | An oncogenic role for sphingosine kinase 2 |
title_short | An oncogenic role for sphingosine kinase 2 |
title_sort | oncogenic role for sphingosine kinase 2 |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323123/ https://www.ncbi.nlm.nih.gov/pubmed/27588496 http://dx.doi.org/10.18632/oncotarget.11714 |
work_keys_str_mv | AT neubauerheidia anoncogenicroleforsphingosinekinase2 AT phamduyenh anoncogenicroleforsphingosinekinase2 AT zeboljuliar anoncogenicroleforsphingosinekinase2 AT morettipaulab anoncogenicroleforsphingosinekinase2 AT petersonamandal anoncogenicroleforsphingosinekinase2 AT leclercqtamaram anoncogenicroleforsphingosinekinase2 AT chanhuasheng anoncogenicroleforsphingosinekinase2 AT powelljasona anoncogenicroleforsphingosinekinase2 AT pitmanmelissar anoncogenicroleforsphingosinekinase2 AT samuelmichaels anoncogenicroleforsphingosinekinase2 AT bonderclaudines anoncogenicroleforsphingosinekinase2 AT creekdarrenj anoncogenicroleforsphingosinekinase2 AT gliddonbrionyl anoncogenicroleforsphingosinekinase2 AT pitsonstuartm anoncogenicroleforsphingosinekinase2 AT neubauerheidia oncogenicroleforsphingosinekinase2 AT phamduyenh oncogenicroleforsphingosinekinase2 AT zeboljuliar oncogenicroleforsphingosinekinase2 AT morettipaulab oncogenicroleforsphingosinekinase2 AT petersonamandal oncogenicroleforsphingosinekinase2 AT leclercqtamaram oncogenicroleforsphingosinekinase2 AT chanhuasheng oncogenicroleforsphingosinekinase2 AT powelljasona oncogenicroleforsphingosinekinase2 AT pitmanmelissar oncogenicroleforsphingosinekinase2 AT samuelmichaels oncogenicroleforsphingosinekinase2 AT bonderclaudines oncogenicroleforsphingosinekinase2 AT creekdarrenj oncogenicroleforsphingosinekinase2 AT gliddonbrionyl oncogenicroleforsphingosinekinase2 AT pitsonstuartm oncogenicroleforsphingosinekinase2 |